<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00869128</url>
  </required_header>
  <id_info>
    <org_study_id>Neu951005</org_study_id>
    <nct_id>NCT00869128</nct_id>
  </id_info>
  <brief_title>A Study of the Efficacy of Prolonged-Release Melatonin Versus Placebo in Diabetic Patients Suffering From Insomnia</brief_title>
  <official_title>A Randomized Double-Blind, Crossover Study Comparing the Efficacy of Prolonged-Release Melatonin Versus Placebo in a 3 Week Treatment of Diabetic Patients Suffering From Insomnia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurim Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neurim Pharmaceuticals Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective - Type 2 uncontrolled diabetic patients often have low endogenous melatonin and
      suffer from sleep disorders. The effect of a prolonged-release melatonin (PRM) formulation on
      glucose lipid metabolism and sleep is studied in type 2 diabetes patients with insomnia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methods: In a randomized, double-blind, crossover study, the subjects were treated for 3
      weeks with 1 tablet per night of 2 mg prolonged-release melatonin or placebo, with one week
      washout period in between. Sleep was objectively monitored by wrist actigraphy. Fasting
      glucose, fructosamine, insulin, C-peptide, triglycerides, cholesterol (total, HDL and LDL)
      and some antioxidants were assessed at baseline and end of each period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 1995</start_date>
  <completion_date type="Actual">March 1997</completion_date>
  <primary_completion_date type="Actual">March 1997</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sleep Efficiency</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>Placebo First</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects were treated for 3 weeks with 1 tablet per night of Placebo and then with 2 mg melatonin (Circadin).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Circadin first</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects were treated for 3 weeks with 1 tablet per night of 2 mg melatonin (Circadin) and then with placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Circadin</intervention_name>
    <description>2 mg prolonged-release melatonin</description>
    <arm_group_label>Placebo First</arm_group_label>
    <arm_group_label>Circadin first</arm_group_label>
    <other_name>Prolonged-release melatonin (2mg)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo First</arm_group_label>
    <arm_group_label>Circadin first</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetic patients with proven presence of the disease who complained of insomnia.

        Exclusion Criteria:

          -  Patients with liver or renal problems (serum creatinine above 1.5 mg/dL).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doron Garfinkel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Evaluation &amp; Rehabilitation and Palliative Unit, Shoham Geriatric Medical Center, Pardes Hana, Israel</affiliation>
  </overall_official>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2008</study_first_submitted>
  <study_first_submitted_qc>March 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2009</study_first_posted>
  <results_first_submitted>December 8, 2008</results_first_submitted>
  <results_first_submitted_qc>March 24, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 25, 2009</results_first_posted>
  <last_update_submitted>March 30, 2009</last_update_submitted>
  <last_update_submitted_qc>March 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Doron Garfinkel</name_title>
    <organization>Shoham Geriatric Medical Center,Pardes Hana 37000, Israel</organization>
  </responsible_party>
  <keyword>melatonin</keyword>
  <keyword>insomnia</keyword>
  <keyword>diabetes</keyword>
  <keyword>sleep</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>36 independently living patients who complained of insomnia and suffered from type 2 diabetes (16 treated with oral hypoglycemic agents and 20 on insulin) entered the study.</recruitment_details>
      <pre_assignment_details>Patients with liver or renal disease (serum creatinine 1.5 mg/dL or higher) were excluded. All 36 patients were randomized and all concluded the crossover randomized and extension parts of the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo First</title>
          <description>Subjects were treated for 3 weeks with 1 tablet per night of Placebo and then with 2 mg melatonin (Circadin).</description>
        </group>
        <group group_id="P2">
          <title>Circadin First</title>
          <description>Subjects were treated for 3 weeks with 1 tablet per night of Circadin 2mg and then with Placebo.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>lack of Compliance</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
          <description>Subjects were treated for 3 weeks with 1 tablet per night of Placebo or Circadin and then 3 weeks of Circadin or Placebo, respectively.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sleep Efficiency</title>
        <description>Sleep efficiency is the percentage of time patients were asleep while in bed as scored by the actigraphic sleep algorithm assessed in the 3 consecutive last nights of each period</description>
        <time_frame>3 weeks</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subjects were treated for 3 weeks with 1 tablet per night of Placebo</description>
          </group>
          <group group_id="O2">
            <title>Circadin</title>
            <description>Subjects were treated for 3 weeks with 1 tablet per night of Circadin 2mg</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Efficiency</title>
          <description>Sleep efficiency is the percentage of time patients were asleep while in bed as scored by the actigraphic sleep algorithm assessed in the 3 consecutive last nights of each period</description>
          <population>ITT</population>
          <units>Percentage of time asleep</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.5" spread="9.6"/>
                    <measurement group_id="O2" value="83.1" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ANOVA, The effect of Circadin was checked by means of 2 x 2 mixed design analysis of variance for repeated measurement.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>ANOVA</method>
            <method_desc>The effect of Circadin was checked by means of 2 x 2 mixed design analysis of variance for repeated measurement.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>D. Garfinkel , MD</name_or_title>
      <organization>Shoham Geriatric Medical Center, Pardes Hana, Israel</organization>
      <phone>Tel: 972-4-6375667</phone>
      <email>dorong@shoham.health.gov.il</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

